Viridian Therapeutics Inc... (VRDN)
| Bid | 12.81 |
| Market Cap | 1.12B |
| Revenue (ttm) | 302K |
| Net Income (ttm) | -269.95M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -4.48 |
| Forward PE | -3.32 |
| Analyst | Buy |
| Ask | 14.57 |
| Volume | 769,758 |
| Avg. Volume (20D) | 983,247 |
| Open | 13.34 |
| Previous Close | 13.13 |
| Day's Range | 13.25 - 13.87 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.85 |
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ...
Analyst Forecast
According to 12 analyst ratings, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 147.36% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
Viridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
